This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (179)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

James P. Bennett, Jr, MD, PhD; Salvatore J. Enna, PhD; David B. Bylund, PhD; J. Christian Gillin, MD; Richard J. Wyatt, MD; Solomon H. Snyder, MD

Arch Gen Psychiatry. 1979;36(9):927-934.

Abstract
• Frontal cerebral cortex brain samples from schizophrenics and controls have been assayed for binding associated with muscarinic cholinergic, serotonin (5HT), -aminobutyric acid (GABA), and β-adrenergic receptors as well as for the activity of the GABA-synthesizing enzyme glutamic acid decarboxylase (GAD). Binding levels of tritium-LSD, presumably associated with postsynaptic 5HT receptors, were reduced 40% to 50% in samples from schizophrenics in three independent studies, whereas no other consistent alteration was observed in levels of binding associated with other receptors or in the activity of GAD. This change in receptor binding levels does not seem to be attributable to postmortem changes, to influences of drugs received by the patients, or to demographic features of the patient populations.

Author Affiliations
From the Departments of Pharmacology and Experimental Therapeutics and Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore (Drs Bennett and Snyder), the Department of Neurobiology and Anatomy, University of Texas Medical School at Houston (Dr Enna), the Department of Pharmacology, University of Missouri School of Medicine, Columbia (Dr Bylund), and the Laboratory of Clinical Psychopharmacology, St Elizabeth's Hospital, Washington, DC (Drs Gillin and Wyatt).

Footnotes
Accepted for publication Nov 1, 1978.

Reprint requests to Departments of Pharmacology and Experimental Therapeutics and Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21205 (Dr Snyder).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Developing Drugs for Cognitive Impairment in Schizophrenia
Breier
Schizophr Bull 2005;31:816-822.
ABSTRACT | FULL TEXT  

In Vivo Determination of Muscarinic Acetylcholine Receptor Availability in Schizophrenia
Raedler et al.
Am. J. Psychiatry 2003;160:118-127.
ABSTRACT | FULL TEXT  

Convergence and Plasticity of Monoaminergic Systems in the Medial Prefrontal Cortex during the Postnatal Period: Implications for the Development of Psychopathology
Benes et al.
Cereb Cortex 2000;10:1014-1027.
ABSTRACT | FULL TEXT  

Serotonin 5-HT2 Receptors in Schizophrenia: A PET Study Using [18F]Setoperone in Neuroleptic-Naive Patients and Normal Subjects
Lewis et al.
Am. J. Psychiatry 1999;156:72-78.
ABSTRACT | FULL TEXT  

Neuroendocrine Response to 5-Hydroxy-L-Tryptophan in Prepubertal Children at High Risk of Major Depressive Disorder
Birmaher et al.
Arch Gen Psychiatry 1997;54:1113-1119.
ABSTRACT  

Familial and developmental abnormalities of frontal lobe function and neurochemistry in schizophrenia
Deakin et al.
J Psychopharmacol 1997;11:133-142.
ABSTRACT  

Serotonin2A Receptors in Schizophrenia: Relation to Suicide-Reply
Laruelle et al.
Arch Gen Psychiatry 1994;51:1003-1004.
ABSTRACT  

Selective Abnormalities of Prefrontal Serotonergic Receptors in Schizophrenia: A Postmortem Study
Laruelle et al.
Arch Gen Psychiatry 1993;50:810-818.
ABSTRACT  

Effect of Neuroleptic Medication on Cerebrospinal Fluid Monoamine Metabolite Concentrations in Schizophrenia: Serotonin-Dopamine Interactions as a Target for Treatment
Kahn et al.
Arch Gen Psychiatry 1993;50:599-605.
ABSTRACT  

m-Chlorophenylpiperazine Effects in Neuroleptic-Free Schizophrenic Patients: Evidence Implicating Serotonergic Systems in the Positive Symptoms of Schizophrenia
Krystal et al.
Arch Gen Psychiatry 1993;50:624-635.
ABSTRACT  

LSD and Schizophrenia
Weaver
Arch Gen Psychiatry 1984;41:631-631.
ABSTRACT  

CSF Levels of {gamma}-Aminobutyric Acid in Schizophrenia: Low Values in Recently Ill Patients
van Kammen et al.
Arch Gen Psychiatry 1982;39:91-97.
ABSTRACT  

Tritiated LSD Binding in Frontal Cortex in Schizophrenia
Whitaker et al.
Arch Gen Psychiatry 1981;38:278-280.
ABSTRACT